https://www.yiliao.com/index.php?action=history&feed=atom&title=GB222
GB222 - 版本历史
2026-04-19T05:30:26Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=GB222&diff=314632&oldid=prev
223.160.138.164：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2026-01-16T04:56:44Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>[[GB222]]</strong>是一种由<strong>[[嘉和生物]]</strong>（[[Genor Biopharma]]）研发的重组全人源化抗<strong>[[血管内皮生长因子]]</strong>（<strong>[[VEGF]]</strong>）单克隆抗体。该药物是<strong>[[贝伐珠单抗]]</strong>（[[Bevacizumab]]，商品名：[[安维汀]]/[[Avastin]]）的生物类似药。[[GB222]]通过特异性结合循环中的[[VEGF-A]]，阻断其与血管内皮细胞表面的受体（[[VEGFR-1]]和[[VEGFR-2]]）结合，从而抑制<strong>[[肿瘤血管生成]]</strong>。临床上，[[GB222]]被广泛应用于治疗<strong>[[转移性结直肠癌]]</strong>、<strong>[[非鳞状非小细胞肺癌]]</strong>、[[胶质母细胞瘤]]及[[肝细胞癌]]等多种实体瘤，是肿瘤抗血管生成治疗体系中的核心生物制剂。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible mw-collapsed" style="width: 320px; float: right; margin: 0 0 25px 25px; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #ffffff 0%, #e0f2fe 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">[[GB222]]</div><br />
<div style="font-size: 0.75em; opacity: 0.85; margin-top: 4px;">[[贝伐珠单抗]]生物类似药 · 点击展开</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 20px; text-align: center; background-color: #f8fafc;"><br />
<div style="padding: 12px; border: 1px solid #e2e8f0; border-radius: 8px; background: #fff; display: inline-block;"><br />
<div style="width: 140px; height: 90px; background-color: #f1f5f9; display: flex; align-items: center; justify-content: center; color: #94a3b8; font-size: 0.8em; padding: 10px; text-align: center;">[[GB222]]抗体分子结合示意图</div><br />
</div><br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">核心靶点：[[VEGF-A]]</div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;"><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 45%;">[[Entrez]]ID</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">7422([[VEGFA]])</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[HGNC]]ID</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">12680</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[UniProt]]</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">P15692</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">分子量</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">约 149 kDa</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">药物类型</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;">[[人源化单克隆抗体]]</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569;">研发厂商</th><br />
<td style="padding: 12px; color: #0f172a;">[[嘉和生物]]</td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">作用机制：切断肿瘤血液供应</h2><br />
<br />
<br />
<p style="margin: 15px 0; text-align: justify;"><br />
[[GB222]]通过高度精准的抗原抗体反应，干预肿瘤赖以生存的微环境：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>中和VEGF配体：</strong>[[GB222]]与循环中的[[VEGF]]结合，使其无法与内皮细胞表面的[[VEGFR-2]]结合。由于[[VEGFR-2]]是启动血管内皮细胞增殖和迁移的关键，阻断此通路可导致现有肿瘤血管退化并抑制新血管生成。</li><br />
<li style="margin-bottom: 12px;"><strong>降低间质压力：</strong>抑制[[VEGF]]可降低肿瘤内微血管的通透性，从而降低[[肿瘤间质压力]]（[[IFP]]）。这一生理变化有助于化疗药物更有效地进入肿瘤核心区域，产生协同作用。</li><br />
<li style="margin-bottom: 12px;"><strong>血管“正常化”：</strong>短期内促使肿瘤血管结构趋向正常化，改善肿瘤内部的乏氧状态，进一步增强放射治疗的效果。</li><br />
</ul><br />
<br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">临床应用矩阵</h2><br />
<br />
<div style="overflow-x: auto; margin: 25px auto; width: 95%;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.9em; text-align: left;"><br />
<tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;"><br />
<th style="padding: 10px; border: 1px solid #cbd5e1; color: #0f172a; width: 25%;">适应症场景</th><br />
<th style="padding: 10px; border: 1px solid #cbd5e1; color: #475569;">联合方案</th><br />
<th style="padding: 10px; border: 1px solid #cbd5e1; color: #1e40af;">临床临床价值</th><br />
</tr><br />
<tr><br />
<td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[晚期结直肠癌]]</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">[[5-FU]] + [[奥沙利铂]]/[[伊立替康]]</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">显著延长[[PFS]]与[[OS]]，作为一线标准治疗。</td><br />
</tr><br />
<tr><br />
<td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[晚期肺腺癌]]</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">[[培美曲塞]] + [[铂类]]</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">在无驱动基因突变人群中显著提升客观缓解率。</td><br />
</tr><br />
<tr><br />
<td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[复发性胶质母细胞瘤]]</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">单药或联用[[化疗]]</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">有效控制脑水肿，改善患者生活质量。</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">诊疗策略：全程管理与风险防范</h2><br />
<p style="margin: 15px 0; text-align: justify;"><br />
[[GB222]]作为抗血管生成药物，其安全性管理需贯穿治疗始终：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>[[高血压]]监测：</strong>这是VEGF通路受抑的最常见副反应。治疗期间应每日监测血压，必要时使用[[血管紧张素转化酶抑制剂]]（[[ACEI]]）干预。</li><br />
<li style="margin-bottom: 12px;"><strong>[[蛋白尿]]筛查：</strong>给药前需进行尿蛋白定量或定性检测。若出现持续性蛋白尿，需根据分级调整剂量或停药。</li><br />
<li style="margin-bottom: 12px;"><strong>围手术期管理：</strong>由于[[VEGF]]涉及正常伤口愈合，重大手术前28天及术后28天（直至伤口完全愈合）应禁用[[GB222]]，以预防[[伤口裂开]]或[[出血]]。</li><br />
<li style="margin-bottom: 12px;"><strong>血栓风险评估：</strong>关注患者是否有血栓栓塞史，治疗期间警惕[[动静脉血栓]]风险。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">关键相关概念</h2><br />
<div style="background-color: #f8fafc; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin: 20px 0;"><br />
<ul style="margin: 0; padding-left: 20px; color: #334155;"><br />
<li style="margin-bottom: 8px;"><strong>[[VEGF]]：</strong>调节血管生成的核心蛋白，肿瘤逃逸的关键驱动力。</li><br />
<li style="margin-bottom: 8px;"><strong>[[安维汀]] (Avastin)：</strong>罗氏研制的贝伐珠单抗原研药，是[[GB222]]的参照标准。</li><br />
<li style="margin-bottom: 8px;"><strong>[[生物类似药]]：</strong>在质量、安全性和有效性上与已获准上市的参照药高度相似的生物药。</li><br />
<li style="margin-bottom: 8px;"><strong>[[抗血管生成]]：</strong>一种不直接杀死肿瘤细胞，而是通过“饿死”肿瘤实现治疗的策略。</li><br />
</ul><br />
</div><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2.2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] <strong>Ferrara N, et al. (2004).</strong> <em>Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer.</em> <strong>[[Nature Reviews Drug Discovery]]</strong>.[Academic Review]<br><br />
<span style="color: #475569;">[权威点评]：该研究奠定了抗血管生成抗体在临床应用中的理论基础。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>Genor Biopharma Clinical Data.</strong> <em>Equivalence study of GB222 versus Bevacizumab in Patients with Advanced Non-squamous NSCLC.</em> <strong>[[Journal of Oncology Pharmacy Practice]]</strong>.<br><br />
<span style="color: #475569;">[核心价值]：证实了GB222与原研药在地学动力学及安全性上的高度一致性。</span><br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;"><br />
<div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;"><br />
[[GB222]] ([[贝伐珠单抗]]) 诊疗生态 · 知识图谱<br />
</div><br />
<table style="width: 100%; border-collapse: collapse; background-color: #ffffff;"><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">关联因子</td><br />
<td style="padding: 10px 15px; color: #334155;">[[VEGF-A]]•[[VEGFR1]]•[[VEGFR2]]•[[HIF-1α]]•[[Neuropilin-1]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">竞品/同类</td><br />
<td style="padding: 10px 15px; color: #334155;">[[安维汀]]•[[齐鲁安可达]]•[[信达苏立信]]•[[雷珠单抗]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">战略实体</td><br />
<td style="padding: 10px 15px; color: #334155;">[[嘉和生物]]•[[罗氏]]•[[NMPA]]•[[ASCO]]</td><br />
</tr><br />
<tr><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">研究前沿</td><br />
<td style="padding: 10px 15px; color: #334155;">[[抗血管生成药物联合PD-1免疫治疗]]•[[针对耐药机制的VEGF/ANG2双抗研发]]•[[早期辅助治疗的获益评估]]</td><br />
</tr><br />
</table><br />
</div><br />
<br />
</div></div>
223.160.138.164